問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
劉惠瑛
下載
2023-03-20 - 2030-06-30
Condition/Disease
Test Drug
Participate Sites6Sites
Recruiting6Sites
2022-05-20 - 2026-12-31
Participate Sites3Sites
Recruiting3Sites
2023-12-01 - 2029-04-30
Participate Sites9Sites
Recruiting9Sites
2025-09-15 - 2036-04-30
MFS is defined as the time from randomisation until the date of first appearance of distant metastases, confirmed by standard clinical imaging [computed tomography (CT)/ magnetic resonance imaging (MRI) and bone scan, or prostate-specific membrane antigen-positron emission tomography (PSMA-PET)], as assessed by blinded independent central review (BICR) or death due to any cause.
saruparib
2025-07-01 - 2029-02-12
Metastatic Hormone-sensitive Prostate Cancer
Tablets
Participate Sites2Sites
Recruiting2Sites
2025-08-01 - 2032-12-31
PSMA-positive Metastatic Castration Resistant Prostate Cancer
[ 225 Ac]Ac-PSMA-617
2025-02-15 - 2028-12-31
Participate Sites4Sites
Recruiting4Sites
全部
